Introduction
Surgery is the therapeutic mainstay in the treatment of gastric cancer (GC), and a prerequisite for cure. However, in many cases curative tumor resection is not possible at diagnosis due to either a nonresectable primary tumor or synchronous metastatic disease. In these patients, chemotherapy is frequently used with the purpose of improving quality and quantity of life. Although documented effects have been seen [1, 2] , they are still limited, with median overall survival rates (OS) of up to about 10 months and no long-term survival in the most recent trials [3, 4] .
Randomized trials have shown that the median survival time can be prolonged by 4-6 months with chemotherapy compared to best supportive care alone [1, 5, 6] . The most optimal regimen remains, however, to be defi ned, although currently used combinations contain either continuous infusion 5-fl uorouracil (5-Fu) or biochemically modulated 5-Fu. In addition, the drugs cisplatin, doxorubicin or epirubicin, etoposide, and more lately irinotecan, docetaxel, and oxaliplatin have been used in various combinations [2, 5, 7] . In the routine treatment of advanced GC, combinations of two or, more recently, three cytostatic drugs are often recommended [4, 5, 7] .
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for other drugs with activity in GC. Phase II trials reported response rates of 31%-58% for irinotecan; a feasible toxicity profi le and median OS of 5-11 months have been reported when the drug was combined with either cisplatin or 5-Fu [10] [11] [12] . A recently published phase III study, comparing a combination of irinotecan/5-Fu with cisplatin/5-Fu, reported overall response rates of 32% and 26% and median OS of 9 and 8.7 months, respectively [3] . For docetaxel, response rates of 37%-56% were reported in combination with cisplatin, and response rates of 28%-86% were reported for docetaxel in combination with 5-Fu in phase II trials [13] [14] [15] [16] [17] [18] [19] . The recently reported phase III V-325 study compared docetaxel in combination with 5-Fu and cisplatin against cisplatin and 5-Fu. Response rates were 37% vs 25% and the median OS was 9.2 vs 8.6 months, respectively (P = 0.02) [4] . The triple combination resulted, however, in signifi cantly increased toxicity.
Combinations of several drugs, thus, result in higher response rates than monotherapy, but are generally more toxic. There is a lack of convincing evidence of clinical benefi t in terms of improved quality of life (QoL) when multiple drug combinations are used rather than sequential treatment, even if subgroups of patients likely benefi t from the most aggressive upfront approach, e.g., for preoperative, tumor-downsizing purposes. Furthermore, following the Goldie and Coldman hypothesis, using active drugs in a predefi ned alternating sequence might reduce the risk of inducing drug resistance [20] . The present study was designed to explore the effi cacy of two newer drug combinations given sequentially, an approach that has not previously been explored in advanced GC.
Methods
This study was a multicenter phase II trial aiming at randomizing 80 chemonaïve patients, older than 18 years, with histologically verifi ed metastatic or locally advanced adenocarcinoma of the stomach or cardia. Prior adjuvant therapy, including chemoradiotherapy after radical surgery was allowed if fi nished more than 6 months before registration. Patients with central nervous system (CNS) metastases or a history of other malignancies than GC, except for curatively treated nonmelanoma skin cancer or in-situ carcinoma of the cervix or prior malignancies treated more than 5 years ago without recurrence, were not included. All patients were required to give written informed consent. The study protocol was approved by the Ethics Committee at the University of Uppsala and the regional committees of the participating hospitals.
All patients had radiologically measurable lesions according to the response evaluation criteria in solid tumors (RECIST), good performance status (WHO ≤2), and adequate hematological, renal, and liver functions (defi ned as hemoglobin [Hb] ≥100 g/l, neutrophils (ANC) ≥ 2.0 × 10 9 /l, platelets ≥ 150 × 10 9 /l, total bilirubin ≤ 1.25 × upper normal limit (UNL), creatinine ≤ 1.25 × UNL, and aspartate aminotransferase [ASAT] , and alanine aminotransferase [ALAT] ≤ 3 × UNL; in the case of liver metastases, ASAT and ALAT ≤ 5 × UNL). Patients with unresolved bowel obstruction, uncontrolled Crohn's disease or ulcerative colitis, or a current history of chronic diarrhea were excluded. All hematological and radiological assessments were done within 8 days and 3 weeks prior to randomization, respectively. The patients started treatment within 10 days from randomization.
Patients were randomly assigned to start with four courses of docetaxel 45 mg/m 2 (arm T) or irinotecan 180 mg/m 2 (arm C) with the simplifi ed de Gramont regimen of 5-Fu/Lv (days 1 and 2 every 2 weeks) ( Fig.  1 ). After 8 weeks, i.e., four courses of treatment, patients switched to the alternative regimen, thus receiving an additional four courses of docetaxel (arm C) or irinotecan (arm T) with the same 5-Fu/Lv-schedule.
Radiological evaluations were conducted by means of computed tomography (CT)scanning or magnetic resonance imaging (MRI) at baseline and after four courses (8 weeks), i.e., at the switch of combinations, and after eight courses (16 weeks), i.e., at the conclusion of the second drug combination.
Quality of life was measured with the European Organization for Research and Treatment of Cancer (EORTC) questionnaire QLQ-C30 at baseline and after the fourth and eighth cycles, i.e., at the conclusion of either of the alternative regimens. These data will be presented in a separate report.
Adverse events were recorded and graded according to the National Cancer Institute (NCI) common toxicity criteria (CTC) version 2.0 before each new treatment course and up to 30 days after the last study drug infusion. In case these criteria were not applicable, the event was defi ned as 1, mild; 2, moderate; 3, severe; or 4, life-threatening.
The primary aim was to explore the effi cacy (objective response rate), and secondary aims included the toxicity profi le, and OS and progression-free survival (PFS) of the planned sequential administration of the two drug combinations. If no complete or partial response (CR+PR) was seen in the fi rst 9 patients in each treatment arm, indicating that the response rate would be less than 30%, the trial would be closed for that treatment arm (Gehan's method phase II trials; step 1). If three or more responses were seen among the fi rst 14 cases an additional 9 patients were to be added (Gehan's method phase II trials; step 2). It would then be possible to estimate the response rate with a stan-dard error of 10%. Several responses were seen in both arms in the fi rst 9 patients. Taking into account anticipated ineligibility, inevaluability, and the second part of the study, the estimated number of patients to be enrolled per treatment arm was 40. OS and PFS were calculated from the date of randomization and assessed according to the Kaplan-Meier method. To test for statistical signifi cance, the t-test, χ 2 test, and log-rank test were used (two-sided). A P value of <0.05 was considered statistically signifi cant.
Results
Eighty-one patients were randomized; 41 to arm T and 40 to arm C. One patient was diagnosed with heart failure directly after randomization and did not start any therapy. Two patients, both in arm T, withdrew their consent before the start of treatment. Thus, a total of 78 patients proceeded to treatment, i.e., 39 in each study arm. Patient characteristics are presented in Table 1 . The two groups were well balanced for prognostic factors, save for gender. The number of patients treated with four and eight cycles, and reasons for dropout are shown in Fig. 2 .
Seventy-one patients were evaluated for response after 8 weeks of treatment with either T or C. Of these, 31 (44%) had a PR. There was no difference in objective response rates between the treatment arms ( Table 2) . After 16 weeks of treatment, a CR or PR as best response were seen in 2 out of 78 (3%) and 30 out of 78 (39%) patients, respectively, again with no difference between treatment arms. Median PFS was 4.9 months for the entire patient population and 4.9 vs 5.0 months for arms C and T, respectively. Forty patients (51%) did not have progressive disease while on the study drug. The median PFS for this subgroup was 8.1 months (range, 4-29 months).
At the time of writing, 18 months after the last patient was included, 69 patients (88%) have died. The long- One patient died of recurrent GC 37 months after randomization and 21 months after surgery. One hundred and twenty-eight grade 3 and nine grade 4 toxicities were registered. In arm T, 55 grade 3 and 6 grade 4 severe adverse events (SAEs) were observed. In arm C, 73 grade 3 and 3 grade 4 SAEs were registered. No signifi cant difference in the overall rate of SAEs was found between the two treatment arms. The most common adverse events are listed in Table 3 . Twenty percent of the included patients experienced hematological toxicity, and 15% reported anorexia, fatigue, or infections, respectively. It can be argued whether dysphagia, which appeared in eight patients, was related to the treatment or to the tumor itself or to previous surgery. No deaths due to therapy-induced toxicity were registered.
Twenty percent of all grade 3 and 30% of grade 4 events were registered after cycles 5 to 8. Thus, the vast (10) 3 (8) 5 (13) CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease term survivors were evenly spread between the treatment arms, i.e., fi ve in each arm. The survival times for these patients vary between 17 and 35 months. The median OS was 11.5 and 10.6 months in arms T and C, respectively. Thus, the effi cacy appears similar (log-rank test: P = 0.3; Fig. 3 ). In this trial, there was no difference in median OS according to gender (log-rank test; P = 0.75).
Five patients (6%), three in arm T and two in arm C, underwent surgery with curative intent after completion of chemotherapy; four had a gastrectomy and one (arm C) a deperitonealization. Four of these patients did not have distant metastatic disease at inclusion, but all had measurable disease considered nonresectable. Three of them had enlarged regional lymph nodes detectable on CT prior to treatment and one had undergone an explorative laparotomy prior to inclusion. Two of these patients are still alive at 28 and 23 months, respectively. majority of SAEs occurred during the fi rst four treatment cycles. This could be explained partly by the fact that most events (58%) occurred in patients who did not complete eight cycles and partly by dose reductions when toxicity was seen during the fi rst treatment cycles. In a considerable proportion of patients, i.e., 43% of those having completed all eight cycles, no grade 3 or 4 SAEs were registered. No grade 3 or 4 SAEs were registered at follow up, 1 to 2 months after completing the eight treatment cycles.
Conclusions
This is the fi rst randomized comparison of prescheduled sequential combination treatment in advanced GC. In addition, it allows a head-to-head comparison of early response rates and toxicity of two of the newer drugs, docetaxel and irinotecan combined with 5-Fu/ Lv. No differences favoring either docetaxel or irinotecan were found with respect to response rates or the total SAE rate after 8 weeks of therapy. Furthermore, no differences in survival outcome could be detected in relation to whether treatment was initiated with docetaxel or irinotecan. This shows that both combinations are effective in GC treatment and that they can be given safely in random order. A phase III study comparing these two treatment arms would be needed to conclude whether one of them has superior effi cacy.
The main interest of our results is, however, that an objective response rate of 41% and a median OS of 11 months were reached in a multicenter study and in a population consisting of 87% of patients with distant metastatic disease. These results are similar to the recently reported effi cacy data of combinations includ- ing cisplatin or combinations of three cytostatic agents (Table 4) [3, 4, 6, 21] . Generally, combinations of irinotecan or docetaxel with 5-Fu have been better tolerated than combinations of cisplatin and 5-Fu, but have resulted in higher gastrointestinal toxicities, with as high as 27% grade 3-4 diarrhea for the combination of irinotecan and 5-Fu [4] . Neutropenia is a major problem for combinations of either irinotecan or docetaxel with cisplatin (66% and 49%, respectively) [4, 11] . This has specially been a problem for the TCF (docetaxel, cisplatin, 5-Fu) combination, where neutropenia occurred in 60% of the patients, resulting, notably, in a 2.5% mortality rate due to febrile neutropenia.
The toxicity of sequential irinotecan and docetaxel in our setup was relatively low if compared to the combinations mentioned above [10, 18, 22] . This is probably a result of "switching" the drug combination after four cycles and thus reducing the typical toxicity of each of the study drugs; i.e., hematological for docetaxel and gastrointestinal for irinotecan. Our results are encouraging, and sequential chemotherapy is a strategy well worth further investigation in the treatment of advanced GC and other gastrointestinal malignancies.
Another important observation in our study was of the small group of patients, with locally advanced, nonresectable tumors at diagnosis, in whom tumor reduction was obtained to such a degree that the patient could be reconsidered for surgery with curative intent. Furthermore, despite the generally poor prognosis of patients with metastatic GC, a subgroup of patients had a considerable gain in the form of comparably durable PFS and OS.
In advanced GC, metastatic disease, poor performance status, weight loss, and male gender are related to poor outcome. In the present series, no difference in OS was found according to gender; this result may have been due to the limited size of the study population.
In conclusion, the results of the GATAC trial indicate that sequential administration of the two described irinotecan and docetaxel combinations is feasible and effective, with median OS similar to those for the commonly used, more toxic, epirubicin cisplatin fl uorouracil (ECF)/epirubicin oxaliplatin Xeloda (EOX)/Taxotere cisplatin fl uracedyl (TCF)-combinations a fi nding which suggests that comparable effi cacy can be obtained with less toxic regimens when they are given in a sequential fashion.
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